195 related articles for article (PubMed ID: 35767251)
1. Bedaquiline, Delamanid, Linezolid and Clofazimine for Treatment of Pre-extensively Drug-Resistant Tuberculosis.
Padmapriyadarsini C; Vohra V; Bhatnagar A; Solanki R; Sridhar R; Anande L; Muthuvijaylakshmi M; Bhatia M; Jeyadeepa B; Taneja G; Balaji S; Shah P; Saravanan N; Chauhan V; Kumar H; Ponnuraja C; Livchits V; Bahl M; Alavadi U; Sachdeva KS; Swaminathan S;
Clin Infect Dis; 2022 Jun; 76(3):e938-46. PubMed ID: 35767251
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China.
He W; Liu C; Liu D; Ma A; Song Y; He P; Bao J; Li Y; Zhao B; Fan J; Cheng Q; Zhao Y
J Glob Antimicrob Resist; 2021 Sep; 26():241-248. PubMed ID: 34214699
[TBL] [Abstract][Full Text] [Related]
3. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
[TBL] [Abstract][Full Text] [Related]
4. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
6. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Hewison C; Khan U; Bastard M; Lachenal N; Coutisson S; Osso E; Ahmed S; Khan P; Franke MF; Rich ML; Varaine F; Melikyan N; Seung KJ; Adenov M; Adnan S; Danielyan N; Islam S; Janmohamed A; Karakozian H; Kamene Kimenye M; Kirakosyan O; Kholikulov B; Krisnanda A; Kumsa A; Leblanc G; Lecca L; Nkuebe M; Mamsa S; Padayachee S; Thit P; Mitnick CD; Huerga H
Clin Infect Dis; 2022 Sep; 75(6):1006-1013. PubMed ID: 35028659
[TBL] [Abstract][Full Text] [Related]
7. Mitigating treatment failure of pulmonary pre-extensively drug-resistant tuberculosis: The role of new and repurposed drugs.
Huang YW; Yu MC; Lin CB; Lee JJ; Lin CJ; Chien ST; Lee CH; Chiang CY
J Microbiol Immunol Infect; 2024 Apr; ():. PubMed ID: 38705821
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Huerga H; Khan U; Bastard M; Mitnick CD; Lachenal N; Khan PY; Seung KJ; Melikyan N; Ahmed S; Rich ML; Varaine F; Osso E; Rashitov M; Salahuddin N; Salia G; Sánchez E; Serobyan A; Rafi Siddiqui M; Grium Tefera D; Vetushko D; Yeghiazaryan L; Holtzman D; Islam S; Kumsa A; Jacques Leblanc G; Leonovich O; Mamsa S; Manzur-Ul-Alam M; Myint Z; Padayachee S; Franke MF; Hewison C
Clin Infect Dis; 2022 Oct; 75(8):1307-1314. PubMed ID: 35243494
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of delamanid- or bedaquiline-containing regimens among children and adolescents with multidrug resistant or extensively drug resistant tuberculosis: A nationwide study from Belarus, 2015-19.
Solodovnikova V; Kumar AMV; Hurevich H; Sereda Y; Auchynka V; Katovich D; Klimuk D; Skrahin A; Setkina S; Charnysh I; Yedilbayev A; Skrahina A
Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470080
[TBL] [Abstract][Full Text] [Related]
10. Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F; Bagdasaryan TR; Borisov S; Howell P; Mikiashvili L; Ngubane N; Samoilova A; Skornykova S; Tudor E; Variava E; Yablonskiy P; Everitt D; Wills GH; Sun E; Olugbosi M; Egizi E; Li M; Holsta A; Timm J; Bateson A; Crook AM; Fabiane SM; Hunt R; McHugh TD; Tweed CD; Foraida S; Mendel CM; Spigelman M;
N Engl J Med; 2022 Sep; 387(9):810-823. PubMed ID: 36053506
[TBL] [Abstract][Full Text] [Related]
11. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
[TBL] [Abstract][Full Text] [Related]
12. Bedaquiline, Delamanid, Linezolid, Clofazimine, and Capreomycin MIC Distributions for Drug Resistance
Guo Y; Yang J; Wang W; Wu X; Wan B; Wang H; Sha W; Yu F
Infect Drug Resist; 2023; 16():7587-7595. PubMed ID: 38107433
[TBL] [Abstract][Full Text] [Related]
13. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
14. Effects of Bedaquiline Combined with Fluoroquinolone and/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: a Retrospective Study.
Li R; Ma JB; Yang H; Yang H; Yang XJ; Wu YQ; Ren F
Microbiol Spectr; 2023 Aug; 11(4):e0104823. PubMed ID: 37310268
[TBL] [Abstract][Full Text] [Related]
15. Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.
Madzgharashvili T; Salindri AD; Magee MJ; Tukvadze N; Avaliani Z; Blumberg HM; Kempker RR; Lomtadze N
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):457-467. PubMed ID: 33347564
[TBL] [Abstract][Full Text] [Related]
16. A four-drug standardized short regimen for highly resistant TB in South-West Nigeria.
Fadeyi MO; Decroo T; Ortuño-Gutiérrez N; Ahmed B; Jinadu A; El-Tayeb O; Adebola W; Kehinde A; Lynen L; Gils T
Int Health; 2024 Jan; 16(1):123-125. PubMed ID: 37026448
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F; Diacon AH; Ngubane N; Howell P; Everitt D; Crook AM; Mendel CM; Egizi E; Moreira J; Timm J; McHugh TD; Wills GH; Bateson A; Hunt R; Van Niekerk C; Li M; Olugbosi M; Spigelman M;
N Engl J Med; 2020 Mar; 382(10):893-902. PubMed ID: 32130813
[TBL] [Abstract][Full Text] [Related]
19. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
20. High clustering rate and genotypic drug-susceptibility screening for the newly recommended anti-tuberculosis drugs among global extensively drug-resistant
Trisakul K; Nonghanphithak D; Chaiyachat P; Kaewprasert O; Sakmongkoljit K; Reechaipichitkul W; Chaiprasert A; Blair D; Clark TG; Faksri K
Emerg Microbes Infect; 2022 Dec; 11(1):1857-1866. PubMed ID: 35792049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
